Veru (NASDAQ:VERU) will be issuing its quarterly earnings data before the market opens on Thursday, December 13th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.
Shares of NASDAQ:VERU opened at $1.38 on Friday. Veru has a 52 week low of $0.93 and a 52 week high of $2.37. The firm has a market capitalization of $83.48 million, a price-to-earnings ratio of -5.52 and a beta of 0.89. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.01 and a quick ratio of 0.80.
VERU has been the subject of a number of recent research reports. Maxim Group reissued a “buy” rating and issued a $10.00 price objective on shares of Veru in a research note on Monday, August 27th. ValuEngine raised shares of Veru from a “hold” rating to a “buy” rating in a research note on Wednesday, August 15th. Zacks Investment Research cut shares of Veru from a “hold” rating to a “sell” rating in a research note on Tuesday, August 21st. Finally, HC Wainwright set a $5.00 price objective on shares of Veru and gave the stock a “buy” rating in a research note on Tuesday, August 28th. Five analysts have rated the stock with a buy rating, Veru presently has an average rating of “Buy” and a consensus target price of $5.50.
COPYRIGHT VIOLATION NOTICE: “Veru (VERU) to Release Quarterly Earnings on Thursday” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/12/08/veru-veru-to-release-quarterly-earnings-on-thursday.html.
Veru Company Profile
Veru Inc operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Further Reading: Analyst Ratings
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.